• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders

ATNX

Athenex, Inc.

$0.20

+0.00 (+0.00%)

Market Metrics

Open

$0.22

Prev. Close

$0.20

Day Low

$0.20

Day High

$0.20

52W Low

$0.08

52W High

$23.80

Market Cap

$0.00B

Volume

1.75M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

22.6%

Avg Negative

5.3%

Avg Neutral

72.1%

News Feed

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Seeking Alpha·8/31/2021·↑ positive

Athenex, Inc. (ATNX) CEO Johnson Lau on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/7/2021·↓ negative

Athenex Provides Second Quarter 2021 Corporate and Financial Update

GlobeNewsWire·8/5/2021·↑ positive

Athenex Announces Additional Licensing Agreements for Tirbanibulin

GlobeNewsWire·7/26/2021·↑ positive

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

GlobeNewsWire·7/22/2021·↑ positive

Athenex Announces European Commission Approval of Klisyri® (tirbanibulin) for the Topical Treatment of Actinic Keratosis

GlobeNewsWire·7/19/2021·↑ positive

Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer

Benzinga·7/6/2021·↑ positive

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

GlobeNewsWire·7/6/2021·↑ positive

SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders

Business Wire·6/7/2021·↓ negative

Athenex Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

GlobeNewsWire·6/4/2021·↑ positive